To verify whether the anti-tumor effects of PRDX1-KD were attributed to downregulation of the NRF2 pathway and enhanced ferroptosis in vivo, NRF2 agonist (TBHQ) or Fer-1 treatment were conducted in CT26PRDX1-KD subcutaneous xenograft model. The gene discussed is NFE2L2; the disease is neoplasm.